These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20616365)

  • 21. Modification of the triplet repeat primed polymerase chain reaction method for detection of the CTG repeat expansion in myotonic dystrophy type 1: application in preimplantation genetic diagnosis.
    Kakourou G; Dhanjal S; Mamas T; Serhal P; Delhanty JD; SenGupta SB
    Fertil Steril; 2010 Oct; 94(5):1674-9. PubMed ID: 20171614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Myotonic dystrophy type 2].
    Kimura T
    Rinsho Shinkeigaku; 2012; 52(11):1267-9. PubMed ID: 23196585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New methods for molecular diagnosis and demonstration of the (CCTG)n mutation in myotonic dystrophy type 2 (DM2).
    Sallinen R; Vihola A; Bachinski LL; Huoponen K; Haapasalo H; Hackman P; Zhang S; Sirito M; Kalimo H; Meola G; Horelli-Kuitunen N; Wessman M; Krahe R; Udd B
    Neuromuscul Disord; 2004 Apr; 14(4):274-83. PubMed ID: 15019706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Muscle pathology in myotonic dystrophy: light and electron microscopic investigation in eighteen patients.
    Nadaj-Pakleza A; Lusakowska A; Sułek-Piątkowska A; Krysa W; Rajkiewicz M; Kwieciński H; Kamińska A
    Folia Morphol (Warsz); 2011 May; 70(2):121-9. PubMed ID: 21630234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a New Molecular Diagnostic Assay for Detection of Myotonic Dystrophy Type 2.
    Valaperta R; Lombardi F; Cardani R; Fossati B; Brigonzi E; Merli I; Sansone V; Merletti G; Spina E; Meola G; Costa E
    Genet Test Mol Biomarkers; 2015 Dec; 19(12):703-9. PubMed ID: 26505324
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Premutation allele pool in myotonic dystrophy type 2.
    Bachinski LL; Czernuszewicz T; Ramagli LS; Suominen T; Shriver MD; Udd B; Siciliano MJ; Krahe R
    Neurology; 2009 Feb; 72(6):490-7. PubMed ID: 19020295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2).
    Botta A; Caldarola S; Vallo L; Bonifazi E; Fruci D; Gullotta F; Massa R; Novelli G; Loreni F
    Biochim Biophys Acta; 2006 Mar; 1762(3):329-34. PubMed ID: 16376058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients.
    Santoro M; Fontana L; Maiorca F; Centofanti F; Massa R; Silvestri G; Novelli G; Botta A
    Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):917-924. PubMed ID: 29291944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy.
    Cardani R; Mancinelli E; Sansone V; Rotondo G; Meola G
    Eur J Histochem; 2004; 48(4):437-42. PubMed ID: 15718211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myotonic Dystrophy Type 1 Clinical, Electrophysiological and Molecular Characterization: Experience at Tertiary Care Centre.
    Khadilkar S; Jagiasi K; Yadav J; Chavan SV; Soni G; Patel B
    J Assoc Physicians India; 2017 Jun; 65(6):32-37. PubMed ID: 28782311
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The unstable CCTG repeat responsible for myotonic dystrophy type 2 originates from an AluSx element insertion into an early primate genome.
    Kurosaki T; Ueda S; Ishida T; Abe K; Ohno K; Matsuura T
    PLoS One; 2012; 7(6):e38379. PubMed ID: 22723857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in myotonic dystrophy type 2.
    Ulane CM; Teed S; Sampson J
    Curr Neurol Neurosci Rep; 2014 Feb; 14(2):429. PubMed ID: 24435591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ZNF9 activation of IRES-mediated translation of the human ODC mRNA is decreased in myotonic dystrophy type 2.
    Sammons MA; Antons AK; Bendjennat M; Udd B; Krahe R; Link AJ
    PLoS One; 2010 Feb; 5(2):e9301. PubMed ID: 20174632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract.
    Liquori CL; Ikeda Y; Weatherspoon M; Ricker K; Schoser BG; Dalton JC; Day JW; Ranum LP
    Am J Hum Genet; 2003 Oct; 73(4):849-62. PubMed ID: 14505273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of short exercise and short exercise with cooling tests in the diagnosis of myotonic dystrophies (DM1 and DM2).
    Gawel M; Szmidt-Salkowska E; Lusakowska A; Nojszewska M; Sulek A; Krysa W; Rajkiewicz M; Seroka A; Kaminska AM
    Muscle Nerve; 2014 Feb; 49(2):277-83. PubMed ID: 23716346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining the performance parameters of a rapid screening tool for myotonic dystrophy type 1 based on triplet-primed PCR and melt curve analysis.
    Lian M; Law HY; Lee CG; Chong SS
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1221-1232. PubMed ID: 27665623
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of full-length
    Alfano M; De Antoni L; Centofanti F; Visconti VV; Maestri S; Degli Esposti C; Massa R; D'Apice MR; Novelli G; Delledonne M; Botta A; Rossato M
    Elife; 2022 Aug; 11():. PubMed ID: 36018009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Absence of a differentiation defect in muscle satellite cells from DM2 patients.
    Pelletier R; Hamel F; Beaulieu D; Patry L; Haineault C; Tarnopolsky M; Schoser B; Puymirat J
    Neurobiol Dis; 2009 Oct; 36(1):181-90. PubMed ID: 19632331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Italian guidelines for molecular analysis in myotonic dystrophies.
    Botta A; Bonifazi E; Vallo L; Gennarelli M; Garrè C; Salehi L; Iraci R; Sansone V; Meola G; Novelli G
    Acta Myol; 2006 Jun; 25(1):23-33. PubMed ID: 17039977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9.
    Liquori CL; Ricker K; Moseley ML; Jacobsen JF; Kress W; Naylor SL; Day JW; Ranum LP
    Science; 2001 Aug; 293(5531):864-7. PubMed ID: 11486088
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.